22157.jpg
Cancer Engineered Antibody Therapeutics Market Analysis 2024: Technology Advances and Increasing Interest from Tier I Pharmaceuticals Driving Growth of Engineered Antibodies
15. August 2024 07:35 ET | Research and Markets
Dublin, Aug. 15, 2024 (GLOBE NEWSWIRE) -- The "Engineered Antibody Therapeutics for Cancer" report has been added to ResearchAndMarkets.com's offering.This study analyzes the emergence of...
Global Antibody Therapeutics Market
Antibody Therapeutics (Monoclonal, Polyclonal, Antibody Fragment, Bispecific) Market Research 2023: Advancements in Antibody Engineering and Growing Focus on Collaborations for Drug Discovery
04. April 2024 04:12 ET | Research and Markets
Dublin, April 04, 2024 (GLOBE NEWSWIRE) -- The "Global Antibody Therapeutics Market by Format (Monoclonal, Polyclonal, Antibody Fragment, Bispecific), Disease Area (Oncology, Autoimmune &...
Crossbow-logo-color_1x.png
Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets
05. März 2024 17:10 ET | Crossbow Therapeutics
Crossbow Therapeutics today announced the nomination of its first development candidate, CBX-250, a T-cell engager for the treatment of myeloid leukemia.
market-digits.jpg
Antibody Therapeutics Market to Witness Remarkable Growth with a CAGR of 13% during the Forecast Period | MarketDigits Richmond, Feb. 22, 2024 (GLOBE NEWSWIRE) -- According to MarketDigits, Antibody Therapeutics Market was valued USD 232 Billion in 2023 and projected to reach USD 535.8 Billion by 2030, growing at a...
22157.jpg
Next Generation Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2031
25. Januar 2024 09:50 ET | Research and Markets
Dublin, Jan. 25, 2024 (GLOBE NEWSWIRE) -- The "Next Generation Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology,...
22157.jpg
Antibody Therapeutics Industry to Reach $631.3 Billion by 2030: Global Market Analysis, Unveiling the Strategies of Leading Players Roche, AbbVie, J&J, and Merck Among Others
24. Januar 2024 13:49 ET | Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Global Antibody Therapeutics Market Size, Share & Trends Analysis, 2023-2030" report has been added to ResearchAndMarkets.com's offering. The...
22157.jpg
Global Antibody Therapeutic Market Research Report 2024-2033 Featuring Key Players - AbbVie, Amgen, Johnson & Johnson Services, Eli Lilly and Co, and Hoffmann-La Roche
05. Januar 2024 04:53 ET | Research and Markets
Dublin, Jan. 05, 2024 (GLOBE NEWSWIRE) -- The "Global Antibody Therapeutic Market: Focus on Format, Disease Area, Route of Administration, End Users, Region, and Competitive Landscape - Analysis and...
MnM_logo_TM_JPG.JPG
Antibody Therapeutics Market is Expected to Reach $479.0 Billion | MarketsandMarkets.
04. Januar 2024 07:30 ET | MarketsandMarkets Research Pvt. Ltd.
Chicago, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Antibody Therapeutics market in terms of revenue was estimated to be worth $247.3 Billion in 2023 and is poised to reach $479.0 billion by 2028, growing at...
22157.jpg
Anti-CD38 Antibody Pipeline Research Report 2023 Featuring Sorrento Therapeutics, I-MAB Biopharma, Takeda, Hangzhou Sumgen Biotech, Wuhan YZY Biopharma, and Biomunex Pharmaceuticals
22. November 2023 08:38 ET | Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Anti-CD38 antibody - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive...
Global Bispecific Antibody Therapeutics Contract Manufacturing Market
The Global Market for Bispecific Antibody Therapeutics Contract Manufacturing 2023-2030: Driven by Demand for Innovative Therapies and Promising Results Seen in Clinical Development
06. November 2023 09:04 ET | Research and Markets
Dublin, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Therapeutics Contract Manufacturing Market 2023-2030" report has been added to ResearchAndMarkets.com's offering. The...